Fentanyl transdermal system and Wound dehiscence - a phase IV clinical study of FDA data

Summary:

Wound dehiscence is found among people who take Fentanyl transdermal system, especially for people who are female, 60+ old.

The phase IV clinical study analyzes which people take Fentanyl transdermal system and have Wound dehiscence. It is created by eHealthMe based on reports of 5,639 people who have side effects when taking Fentanyl transdermal system from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 28, 2023

5,639 people reported to have side effects when taking Fentanyl transdermal system.
Among them, 17 people (0.3%) have Wound dehiscence.

What is Fentanyl transdermal system?

Fentanyl transdermal system has active ingredients of fentanyl. It is often used in pain. eHealthMe is studying from 5,728 Fentanyl transdermal system users for its effectiveness, alternative drugs and more.

What is Wound dehiscence?

Wound dehiscence (a surgical incision reopens either internally or externally) is found to be associated with 1,257 drugs and 650 conditions by eHealthMe.

Number of Fentanyl transdermal system and Wound dehiscence reports submitted per year:

Could Fentanyl transdermal system cause Wound dehiscence?

Gender of people who have Wound dehiscence when taking Fentanyl transdermal system *:

female: 100 %
male: 0.0 %

Age of people who have Wound dehiscence when taking Fentanyl transdermal system *:

Common drugs people take besides Fentanyl transdermal system *:

Common side effects people have besides Wound dehiscence *:

Wound Infection Pseudomonas: 16 people, 94.12%
Hyperkalemia (damage to or disease of the kidney): 16 people, 94.12%
Hepatic Cyst: 16 people, 94.12%
Heart Disease: 16 people, 94.12%
Heart Attack: 16 people, 94.12%
Haematuria (presence of blood in urine): 16 people, 94.12%
Haemarthrosis (haemarthrosis is where blood is able to enter the joint capsule): 16 people, 94.12%
Groin Pain: 16 people, 94.12%
General Physical Health Deterioration (weak health status): 16 people, 94.12%
Gastrointestinal Haemorrhage (bleeding gastrointestinal tract): 16 people, 94.12%

Common conditions people have *:

Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 16 people, 94.12%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 15 people, 88.24%
Pancreatic Carcinoma Metastatic (pancreatic cancer- metastatic): 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Fentanyl transdermal system and have Wound dehiscence?

Check whether Wound dehiscence is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Browse all side effects of Fentanyl transdermal system:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Wound dehiscence treatments and more:

Wound dehiscence (4,641 reports)

COVID vaccines that are related to Wound dehiscence:

Common drugs associated with Wound dehiscence:

All the drugs that are associated with Wound dehiscence:

Wound dehiscence (1,257 drugs)

Common conditions associated with Wound dehiscence:

All the conditions that are associated with Wound dehiscence:

Wound dehiscence (650 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on fentanyl (the active ingredients of Fentanyl transdermal system) and Fentanyl transdermal system (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.